Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine. | Following its recently announced partnership with Novo Nordisk,

Muse Spark, as what Meta Platforms (NASDAQ:META | META Price Prediction) is calling its much-anticipated closed-source model, which used to go by the codename Avocado. Undoubtedly, it’s an interesting name,

Alibaba Group Holding Ltd. launched a new AI model that can be used to develop games and generate videos simulating the real world, expanding its suite of products to challenge Tencent Holdings Ltd. as it looks to monetize the technology.

Meta on Wednesday announced its first major model since CEO Mark Zuckerberg rebooted the company’s AI efforts last year under a new division called Meta Intelligence Labs. The model, called Muse Spark, is a step toward Zuckerberg’s vision of “personal superintelligence,” the company says, and for now, it will remain closed source.

Anthropic is discussing its frontier AI model Mythos with the Trump administration, the firm's co-founder said on Monday, even after the Pentagon cut off business with

OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs.

Alibaba Group launched Happy Oyster on Thursday, doubling down on its artificial-intelligence ambitions and joining Google in the foray into world models. The launch comes just weeks after the Chinese company released an AI video-generation model that topped a global ranking.

Anthropic's Mythos AI model sparked cybersecurity concerns, but some think it's been overhyped. Here's what smart people re saying.

That human-accountable model makes the most sense to me. By all means, integrate AI into the systems employees already use and let it take over the repetitive, time-consuming drudgery of the job. But we still need someone to vet the results and decide whether it makes sense.